COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN SEROPOSITIVE, EROSIVE EARLY RHEUMATOID ARTHRITIS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0

作者：

Marinheiro, P. ^{[1
]}

Faustino, P. ^{[1
]}

Watanabe, S. ^{[2
]}

Lima, P. ^{[2
]}

机构：

[1] Bristol Myers Squibb, New York, NY USA

[2] IQVIA, Sao Paulo, Brazil

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

111

引用

页码：136 / 136

页数：1

共 50 条

[21] Cost minimization analysis of rituximab versus infliximab, adalimumab and etanercept for rheumatoid arthritis from a payer perspective in Brazil
Saggia, M. G.
Santos, E. A.
Nasciben, V
VALUE IN HEALTH, 2007, 10 (06) : A247 - A247
[22] COST PER RESPONDER ANALYSIS OF GUSELKUMAB VS ADALIMUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Saad, R.
Santana, P.
Fioratti, C.
Rachid, M. L.
Decimoni, T. C.
Laranjeira, F. O.
Brunelli, M. J.
VALUE IN HEALTH, 2019, 22 : S377 - S377
[23] The cost-effectiveness of abatacept versus rituximab in patients with rheumatoid arthritis: A perspective of the Canadian publicly funded health care system
Yuan, Y.
Maier-Moldovan, M.
Maclean, R.
L'Italien, G. J.
VALUE IN HEALTH, 2008, 11 (03) : A257 - A257
[24] COST-UTILITY ANALYSIS AND EFFICIENCY FRONTIER APPROACH OF TAFASITAMAB IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Fahham, L.
Dias, L.
Amaral, L. Murta
Mazzuco, C.
Araujo, G.
VALUE IN HEALTH, 2024, 27 (12)
[25] COST PER RESPONDER ANALYSIS OF USTEKINUMAB VERSUS SECUKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Araujo, R. L.
Scaccabarozzi, L.
Asano, E.
VALUE IN HEALTH, 2017, 20 (05) : A220 - A220
[26] COST-EFFECTIVENESS ANALYSIS OF NETUPITANT/ PALONOSETRON FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Araujo, G.
Silva, H. M.
Picoli, R. M.
VALUE IN HEALTH, 2023, 26 (12) : S93 - S93
[27] Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System
Gonzalez, Julia
Andrade, Diana Carolina
Niu, Jianli
CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1436 - E1442
[28] COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Fioratti, C.
Rachid, M. L.
Baida, R.
Decimoni, T.
Brunelli, M. J.
VALUE IN HEALTH, 2019, 22 : S618 - S618
[29] COST PER RESPONDER ANALYSIS OF BIOLOGIC TREATMENTS FOR ULCERATIVE COLITIS IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Souza, P. V. S.
Baida, R.
Gomes, T. N. F.
VALUE IN HEALTH, 2020, 23 : S532 - S532
[30] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Souza, P.
Puopolo, G. R.
Leme-Souza, R.
VALUE IN HEALTH, 2019, 22 : S847 - S847

← 1 2 3 4 5 →